New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2013
07:34 EDTCYTKCytokinetics presents Phas IIA clinical trial data of tirasemtiv
Cytokinetics announced the presentation of positive data from a completed Phase IIa "Evidence of Effect" clinical trial of tirasemtiv in patients with generalized myasthenia gravis, or MG. Tirasemtiv selectively activates the fast skeletal muscle troponin complex by increasing its sensitivity to calcium, thereby increasing skeletal muscle force in response to neuronal input and delaying the onset and reducing the degree of muscle fatigue. Tirasemtiv is being evaluated as a potential treatment for amyotrophic lateral sclerosis, or ALS, in Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS, an international Phase IIb clinical trial that is now enrolling patients.
News For CYTK From The Last 14 Days
Check below for free stories on CYTK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
07:21 EDTCYTKHeart Failure Society of America to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use